Page 21 - Flipbook
P. 21
PRESENCE OF CARDIAC RISK FACTORS IMPACTS RISK OF
CV MORTALITY WITH ADT
Known CAD resulting in
40% No comorbidity 40% 1 CV risk factor 40% heart failure or MI
Brachytherapy 30% 30% Log rank p = 0.004
30%
All-cause mortality 20% Log rank p = 0.51 20% Log rank p = 0.17 20%
With neoadjuvant HT
Without neoadjuvant HT
10%
10%
10%
0% 0% 0%
0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8
No. at risk Time following prostate brachytherapy, years Time following prostate brachytherapy, years Time following prostate brachytherapy, years
Brachytherapy
Neoadjuvant HT 780 699 532 288 98 646 566 373 176 55 95 79 58 30 8
No neoadjuvant HT 1,873 1,582 1,073 607 282 1,522 1,247 765 392 151 161 135 97 46 18
Presence of pre-existing MACE (CHF, ischemic heart disease, arrhythmia, stroke, prior MI)
may increase risk of further events while on ADT
CAD Coronary artery disease CHF Congestive heart failure HT Hormone therapy Nanda A, et al. JAMA 2009;302:866-73
